Half-year report · Q2
3353.TEDINET S100UIUM
Period2024-03-01 → 2024-08-31
Filed2024-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.7bn | 2024-03-01 → 2024-08-31 | Cons. | Net sales |
| Revenue | ¥39.9bn | 2023-03-01 → 2024-02-29 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.5bn | 2023-03-01 → 2023-08-31 | Cons. | Net sales |
| Operating income | ¥828m | 2024-03-01 → 2024-08-31 | Cons. | Operating income |
| Operating income | ¥603m | 2023-03-01 → 2023-08-31 | Cons. | Operating income |
| Ordinary income | ¥853m | 2024-03-01 → 2024-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-03-01 → 2024-02-29 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥697m | 2023-03-01 → 2023-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2024-03-01 → 2024-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥776m | 2023-03-01 → 2023-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥710m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥444m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥728m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss |
| Net income | ¥469m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss |
| Total assets | ¥33.1bn | at 2024-08-31 | Cons. | Assets |
| Total assets | ¥31.7bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥18.7bn | at 2024-08-31 | Cons. | Liabilities |
| Total liabilities | ¥17.8bn | at 2024-02-29 | Cons. | Liabilities |
| Net assets / equity | ¥14.4bn | at 2024-08-31 | Cons. | Net assets |
| Net assets / equity | ¥13.8bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥13.1bn | at 2023-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.2bn | at 2024-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.7bn | at 2024-02-29 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.1bn | at 2024-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2023-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥848m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥675m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.2bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥338m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥354m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥278m | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥217m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥188.75 | 2024-03-01 → 2024-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.7 | 2023-03-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.26 | 2023-03-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.6% | at 2024-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.8% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.9% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2024-08-31 | −¥110m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥551m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥128m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥7.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥6.7bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥399m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥194m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥65m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2024-08-31 | ¥23.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2024-08-31 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥401m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2024-08-31 | ¥938m |
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-08-31 | −¥296m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥688m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥111m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥2.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥1.6bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥470m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥34m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥66m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-08-31 | ¥17.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥472m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-08-31 | ¥899m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人ト ー マ ツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)神 野 敦 生 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)牧 野 秀 俊 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 17450480000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 22665446000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 39900988000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 696659000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 853019000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1751894000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 444369000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 709504000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 1039786000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 555192000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 638593000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 1381275000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 13090270000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 14394490000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 13841190000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 28480670000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 33115610000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 31659490000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 118.26 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 188.75 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 276.70 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.439 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.416 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.418 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 847550000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 1501567000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 4277397000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -338155000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -675404000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -3218889000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -217387000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -354484000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 277758000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 6545111000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 8075427000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 7589368000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4070000 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 1020000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.2711 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |